Know Cancer

forgot password

Phase II Study of Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy

Phase 2
18 Years
Open (Enrolling)
Bladder Cancer

Thank you

Trial Information

Phase II Study of Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy

Inclusion Criteria:

- Age ≥ 18 years

- Histologically confirmed diagnosis of urothelial carcinoma of the bladder, urethra,
ureter, or renal pelvis by MSKCC pathology review

- Measurable disease as determined by RECIST v1.1 on initial pretreatment staging CT
scan of the chest, abdomen, and pelvis (or MRI if clinically appropriate). (Note: A
chest x-ray may be performed as an alternative to a CT scan of the chest.)

- Ineligible for cisplatin based on one or more of the following:

- Calculated creatinine clearance of < 60 mL/min (but ≥ 30 mL/min)

- Karnofsky Performance Status (KPS) 60-70% (ECOG PS 2)

- Grade 2 ≥ hearing loss

- Grade 2 ≥ peripheral neuropathy

- Karnofsky Performance Status ≥ 60%

- 10 unstained slides or paraffin embedded tissue block obtained from pretreatment
tumor specimens for immunohistochemistry. (Note: One paraffin block or 10
freshly-prepared unstained slides from the most representative single paraffin
embedded tumor tissue block should be submitted. Slides from the primary tumor are
preferred. If both the primary and metastatic tumor blocks are available, 10 slides
from each of the sites should be submitted. If tissue from the primary tumor is not
available, a paraffin block or unstained slides from a metastatic site are
acceptable. Fine needle aspirates (FNAs) have insufficient tumor tissue and are not

- Adequate organ system function as defined:

- Absolute neutrophil count (ANC) ≥1.5 X 109/L

- Hemoglobin ≥9 g/dL (5.6 mmol/L) (Note: Subjects may not have had a transfusion
within 7 days of screening assessment.)

- Platelets ≥100 X 109/L

- Prothrombin time (PT) or international normalized ratio (INR) ≤1.2 X ULN (Note:
Subjects receiving anticoagulant therapy are eligible if their INR is stable and
within the recommended range for the desired level of anticoagulation.)

- Activated partial thromboplastin time (aPTT) ≤1.2 X ULN

- Total bilirubin ≤1.5 X ULN

- Alanine amino transferase (ALT) and Aspartate aminotransferase (AST)

≤2.5 X ULN (Note: Concomitant elevations in bilirubin and AST/ALT above 1.0 x
ULN (upper limit of normal) are not permitted.)

- Calculated creatinine clearance (ClCR) ≥30 mL/min using the CKD-EPI equation:
eGFR = 141 x min(Scr/k, 1)a x max(Scr/k, 1)-1.209 x 0.993 Age x 1.018 [if
female] x 1.159 [if black] Scr is serum creatinine, k is 0.7 for females and 0.9
for males, a is - 0.329 for females and -0.411 for males, min indicates the
minimum of Scr/k or 1, and max indicates the maximum of Scr/k or 1

- Urine Protein to Creatinine Ratio (UPC)d <1 (Note: If UPC ≥1, then a 24- hour
urine protein must be assessed. Subjects must have a 24-hour urine protein value
<1 g to be eligible.)

Exclusion Criteria:

- Prior treatment with systemic chemotherapy (prior intravesical therapy is permitted)

- Prior malignancy (Note: Subjects who have had another malignancy and have been
disease-free for 5 years subjects with a history of completely resected
non-melanomatous skin carcinoma, subjects with successfully treated in situ
carcinoma, or subjects who have had adenocarcinoma of the prostate that has been
definitively treated with a post-treatment PSA that is non-detectable are eligible.)

- History or clinical evidence of central nervous system (CNS) metastases or
leptomeningeal carcinomatosis, except for individuals who have previously-treated CNS
metastases, are asymptomatic, and have had no requirement for steroids or
anti-seizure medication for 6 months prior to first dose of study drug. Screening
with CNS imaging studies (computed tomography [CT] or magnetic resonance imaging
[MRI]) is required only if clinically indicated or if the subject has a history of
CNS metastases.

- Clinically significant gastrointestinal abnormalities that may increase the risk for
gastrointestinal bleeding including, but not limited to:

- Active peptic ulcer disease

- Known intraluminal metastatic lesion/s with risk of bleeding

- Inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease), or other
gastrointestinal conditions with increased risk of perforation

- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal
abscess within 28 days prior to beginning study treatment Clinically significant
gastrointestinal abnormalities that may affect absorption of investigational
product including, but not limited to:

- Malabsorption syndrome

- Major resection of the stomach or small bowel

- Active liver disease such as cirrhosis, chronic active hepatitis, or chronic
persistent hepatitis

- Presence of uncontrolled infection Corrected QT interval (QTc) > 480 msecs using
Bazett's formula

o If QTc interval is > 480 msecs, then 2 additional ECGs should be obtained over a
brief period of time (e.g., within approximately 15-20 minutes) to confirm the
abnormality. The average QTc interval will be determined from the 3 ECG tracings by
manual evaluation and will be used to determine if the subject will be excluded from
the study. If the average QTc interval is >480 msec, then the subject is not eligible
to participate in the study Previous history of QTc prolongation as a result of other
medication that required discontinuation of that medication

- Congenital long QT syndrome or 1st degree relative with unexplained sudden death
under 40 years of age

- Use of any concomitant medication (during treatment with pazopanib or within 14 days
of starting treatment) that are high risk for QTc prolongation or may induce Torsades
de Pointes.

- History of any one or more of the following cardiovascular conditions within the past
6 months:

- Cardiac angioplasty or stenting

- Myocardial infarction Unstable angina

- Coronary artery bypass graft surgery

- Symptomatic peripheral vascular disease

- Class III or IV congestive heart failure, as defined by the New York Heart
Association (NYHA)

- Poorly controlled hypertension [defined as systolic blood pressure (SBP) of ≥140 mmHg
or diastolic blood pressure (DBP) of ≥ 90mmHg] (Note: Initiation or adjustment of
antihypertensive medication(s) is permitted prior to study entry. At least 24 hours
after initiation or adjustment of antihypertensive medication (s), BP must be
re-assessed on two occasions that are separated by a minimum of 1 hour; on each of
these occasions, the mean (of 3 readings) SBP / DBP values from each BP assessment
must be <140/90 mmHg in order for a subject to be eligible for the study.)

- History of cerebrovascular accident including transient ischemic attack (TIA),
pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6
months. (Note: Subjects with recent DVT who have been treated with therapeutic
anti-coagulating agents for at least 6 weeks are eligible.)

- Prior major surgery or trauma within 28 days prior to first dose of study drug and/or
presence of any non-healing wound, fracture, or ulcer (procedures such as catheter
placement not considered to be major).

- Evidence of active bleeding or bleeding diathesis. Known endobronchial lesions and/or
lesions infiltrating major pulmonary vessels

- Hemoptysis in excess of 2.5 mL (or one half teaspoon) within 8 weeks of first dose of
study drug.

- Any serious and/or unstable pre-existing medical, psychiatric, or other condition
that could interfere with subject's safety, provision of informed consent, or
compliance to study procedures.

- Unable or unwilling to discontinue use of prohibited medications listed in
(Concomitant Therapy) for at least 14 days or five half-lives of a drug (whichever is
longer) prior to the first dose of study drug and for the duration of the study

- Treatment with any of the following anti-cancer therapies:

- Radiation therapy, surgery or tumor embolization within 14 days prior to the
first dose of pazopanib OR

- Immunotherapy, biologic therapy, investigational therapy or hormonal therapy
within 14 days or five half-lives of a drug (whichever is longer) prior to the
first dose of pazopanib Administration of any non-oncologic investigational drug
within 30 days or 5 half lives whichever is longer prior to receiving the first
dose of study treatment

- Any ongoing toxicity from prior anti-cancer therapy that is >Grade 1 and/or that is
progressing in severity

- Women who are pregnant or breast feeding (Female subjects who are lactating should
discontinue nursing prior to the first dose of study drug and should refrain from
nursing throughout the treatment period and for 14 days following the last dose of
study drug.)

- Adults of child-bearing potential not employing an effective method of birth control
for two weeks prior to study start and 21 days after the last dose. All women of
child-bearing potential must have a negative serum pregnancy test. Women of
child-bearing potential are defined as sexually mature women who have not undergone a
hysterectomy, bilateral oophorectomy (ovariectomy), or bilateral tubal ligation OR
have not experienced total cessation of menses for ≥ 1 year and are older than 45
years in age, In questionable cases, the patient must have a follicle stimulating
hormone (FSH) value >40 mIU/mL and an estradiol value < 40pg/mL (<140 pmol/L).
Effective methods of birth control are defined in section 9.9 (Contraception

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

progression free survival (PFS)

Outcome Description:

Progression Free Survival will be calculated from the start of treatment until progressive disease or death. Patients who die before documented progression will be considered failures at their time of death. If the patient did not progress or die, the patient will be censored on the date of last follow-up. Response and progression will be evaluated in this study using the international criteria by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

Outcome Time Frame:

2 years

Safety Issue:


Principal Investigator

Dean Bajorin, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center


United States: Food and Drug Administration

Study ID:




Start Date:

June 2012

Completion Date:

June 2014

Related Keywords:

  • Bladder Cancer
  • renal pelvis
  • GW786034 (PAZOPANIB)
  • 11-191
  • Urinary Bladder Neoplasms
  • Carcinoma
  • Carcinoma, Transitional Cell



Memorial Sloan-Kettering Cancer Center New York, New York  10021
Memorial Sloan-Kettering Cancer Center at Mercy Medical Center Rockville Centre, New York  11570
Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center Sleepy Hollow, New York  10591
Memoral Sloan Kettering Cancer Center Basking Ridge, New Jersey  
Memorial Sloan-Kettering Cancer Center @ Suffolk Commack, New York  11725